For many patients diagnosed with non-Hodgkin lymphoma, R-CHOP is the first treatment they receive. In fact, R-CHOP has been the standard first-line therapy for several common types of lymphoma for more than two decades.

While many patients achieve long-lasting remission, some unfortunately experience a relapse, while others find that their lymphoma does not respond adequately to treatment.
One of the most common questions patients ask is: "What happens if R-CHOP doesn't work?"

The good news is that several effective treatment options are available, including stem cell transplantation, CAR-T therapy, bispecific antibodies, and newer targeted treatments.

What Is R-CHOP?

R-CHOP is a combination of five medications:

  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone

It is commonly used to treat:

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma (in some situations)
  • Transformed Lymphoma
  • Primary Mediastinal B-Cell Lymphoma
  • Other aggressive B-cell lymphomas

Many patients achieve complete remission after R-CHOP, but unfortunately this is not always the case.

When Is R-CHOP Considered to Have Failed?

Doctors generally consider R-CHOP unsuccessful if:

  • The lymphoma does not respond adequately during treatment.
  • The disease progresses during treatment.
  • The lymphoma returns after an initial remission.

The timing of relapse is important.
Patients who relapse within 12 months of completing R-CHOP are often considered for more advanced treatment approaches, including CAR-T therapy.

Treatment Options After R-CHOP

The best treatment depends on:

  • The lymphoma subtype
  • The patient's age and general health
  • Previous treatments
  • How quickly the disease returned
  • Whether the lymphoma remains sensitive to chemotherapy

Salvage Chemotherapy

Traditionally, patients who relapse after R-CHOP receive a second-line chemotherapy regimen, often called salvage therapy.
Examples include:

  • R-ICE
  • R-DHAP
  • R-GDP

The goal is to reduce the lymphoma burden and determine whether the disease remains responsive to treatment.
Patients who respond well may proceed to stem cell transplantation.

Stem Cell Transplantation (commonly known as a bone marrow transplant)

For many years, autologous stem cell transplantation (sometimes called a bone marrow transplant) was the standard treatment for eligible patients whose lymphoma returned after R-CHOP.
The procedure involves:

  1. Collection of the patient's stem cells.
  2. High-dose chemotherapy.
  3. Reinfusion of the stem cells.

Stem cell transplantation remains an important option for some patients.
However, treatment approaches have changed significantly with the introduction of CAR-T therapy.

CAR-T Therapy

CAR-T therapy has transformed the treatment landscape for patients with relapsed or refractory B-cell lymphomas.
The treatment uses the patient's own immune cells, which are genetically modified to recognize and attack lymphoma cells.
Several CAR-T products are now approved for patients with aggressive B-cell lymphomas that have relapsed after previous treatment.

In many centers worldwide, CAR-T therapy is now considered a preferred option for selected patients whose lymphoma returns after first-line treatment.

Bispecific Antibodies

Another major development is the introduction of bispecific antibodies.
These medications help the immune system recognize and attack lymphoma cells.

  • Epcoritamab
  • Glofitamab
  • Mosunetuzumab

For some patients, bispecific antibodies may be considered before or after CAR-T therapy.

Targeted Therapies

Depending on the lymphoma subtype, targeted therapies may also be available.
Examples include:

  • Polatuzumab Vedotin
  • Tafasitamab
  • Lenalidomide combinations
  • BTK inhibitors for certain lymphoma subtypes

Treatment selection is highly individualized and should be discussed with an experienced lymphoma specialist.

Conclusion

A relapse after R-CHOP can be frightening, but it does not mean that treatment options have been exhausted.
Today, patients may have access to:

  • Salvage chemotherapy
  • Stem cell transplantation
  • CAR-T therapy
  • Bispecific antibodies
  • Targeted therapies
  • Clinical trials

The most appropriate treatment depends on the individual patient and the specific characteristics of the lymphoma.
For many patients with relapsed or refractory lymphoma, CAR-T therapy has become one of the most important advances in treatment over the past decade and may offer a new opportunity for long-term disease control.

Sources:
American Cancer Society – Non-Hodgkin Lymphoma
The Leukemia & Lymphoma Society – Diffuse Large B-Cell Lymphoma (DLBCL)
National Cancer Institute – CAR T-Cell Therapy
National Cancer Institute – Adult Non-Hodgkin Lymphoma Treatment (PDQ®)

Publication date: June 2026

Links
Initiating your CAR-T medical inquiry >>
CAR-T testimonials